Reviewer's report

**Title:** Sodium Glucose Co-Transport 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Double-Blind Controlled Trials

**Version:** 1  
**Date:** 27 October 2013  
**Reviewer:** Ching-Chu Chen

**Reviewer's report:**

Minor Essential Revisions
1. Introduction: paragraph 2, "Intensive therapy of patinets with type 2..." In fact, DCCT (ref. 6) is a study of type 1 diabetes.
2. Results: Please indicate Fig 3 in paragraph 3; Fig 4 and Fig 5 in paragraph 4. Please report subtotal ORs (adverse events) of ipragliflozin in paragraph 4. Regarding the discontinuation of medication, the overall OR = 1.05, 95% CI, 0.81 to 1.36, instead of 1.35 (based on the report of fig 5), at the end of paragraph 4.
3. Authors should revise the format of the references carefully. The name of the first author of reference 29 is Yale JF.
4. Please report the frequency of dosing in table 1 and correct a typing error Wilding JPH et al 18().

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

Yes, I have received speaker fee, modulator fee or reimbursements for an international meeting from Boehringer Ingelheim, Bristol Myers Squibb, AstraZeneca in the past 5 years. These companies manufacture or co-promote sGLT2 inhibitor.